RN0191

RN0191 is a novel small interfering RNA (siRNA) therapeutic designed to inhibit the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that regulates low-density lipoprotein cholesterol (LDL-C) levels. By targeting PCSK9 mRNA, RN0191 reduces PCSK9 protein synthesis, leading to increased LDL receptor availability and enhanced clearance of LDL-C from the bloodstream. The drug utilizes GalNAc conjugation for targeted delivery to hepatocytes via subcutaneous injection. Developed by Rona Therapeutics and Ikaria Bioscience, RN0191 has demonstrated robust reductions in both PCSK9 (>85%) and LDL-C (>55%) in Phase 1 clinical trials involving healthy adults with elevated LDL-C not on lipid-lowering therapy. The safety profile was favorable with only mild transient adverse events reported. Its durable effect suggests potential for bi-annual dosing regimens[4][5][6].